These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21114823)

  • 1. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.
    Bercoff DP; Triqueneaux P; Lambert C; Oumar AA; Ternes AM; Dao S; Goubau P; Schmit JC; Ruelle J
    Retrovirology; 2010 Nov; 7():98. PubMed ID: 21114823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
    Roquebert B; Damond F; Collin G; Matheron S; Peytavin G; Bénard A; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
    J Antimicrob Chemother; 2008 Nov; 62(5):914-20. PubMed ID: 18718922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
    Ni XJ; Delelis O; Charpentier C; Storto A; Collin G; Damond F; Descamps D; Mouscadet JF
    Retrovirology; 2011 Aug; 8():68. PubMed ID: 21854605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.
    Parczewski M; Bander D; Urbańska A; Boroń-Kaczmarska A
    BMC Infect Dis; 2012 Dec; 12():368. PubMed ID: 23259737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.
    Cavaco-Silva J; Abecasis A; Miranda AC; Poças J; Narciso J; Águas MJ; Maltez F; Almeida I; Germano I; Diniz A; Gonçalves Mde F; Gomes P; Cunha C; Camacho RJ;
    PLoS One; 2014; 9(3):e92747. PubMed ID: 24681625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Lataillade M; Chiarella J; Kozal MJ
    Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
    Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
    J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 integrase inhibitor resistance and its clinical implications.
    Blanco JL; Varghese V; Rhee SY; Gatell JM; Shafer RW
    J Infect Dis; 2011 May; 203(9):1204-14. PubMed ID: 21459813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.
    Gottlieb GS; Smith RA; Dia Badiane NM; Ba S; Hawes SE; Toure M; Starling AK; Traore F; Sall F; Cherne SL; Stern J; Wong KG; Lu P; Kim M; Raugi DN; Lam A; Mullins JI; Kiviat NB;
    PLoS One; 2011; 6(7):e22204. PubMed ID: 21765953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.
    Garrido C; Geretti AM; Zahonero N; Booth C; Strang A; Soriano V; De Mendoza C
    J Antimicrob Chemother; 2010 Feb; 65(2):320-6. PubMed ID: 20007331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of transmitted resistance to raltegravir and selective pressure among HIV-1-infected patients on a failing HAART in Sao Paulo, Brazil.
    Mantovani NP; Azevedo RG; Rabelato JT; Sanabani S; Diaz RS; Komninakis SV
    J Clin Microbiol; 2012 Jun; 50(6):2122-5. PubMed ID: 22403424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals.
    Dimonte S; Babakir-Mina M; Aquaro S; Perno CF
    Infection; 2013 Dec; 41(6):1097-102. PubMed ID: 23620062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative prediction of integrase inhibitor resistance from genotype through consensus linear regression modeling.
    Van der Borght K; Verheyen A; Feyaerts M; Van Wesenbeeck L; Verlinden Y; Van Craenenbroeck E; van Vlijmen H
    Virol J; 2013 Jan; 10():8. PubMed ID: 23282253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
    Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
    Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
    Varghese V; Liu TF; Rhee SY; Libiran P; Trevino C; Fessel WJ; Shafer RW
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1323-6. PubMed ID: 20961278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.
    Fransen S; Gupta S; Frantzell A; Petropoulos CJ; Huang W
    J Virol; 2012 Jul; 86(13):7249-55. PubMed ID: 22553340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
    Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
    HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of raltegravir resistance profile in an HIV type 2-infected patient.
    Xu L; Anderson J; Garrett N; Ferns B; Wildfire A; Cook P; Workman J; Graham S; Smit E
    AIDS Res Hum Retroviruses; 2009 Aug; 25(8):843-7. PubMed ID: 19618998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.